Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02903160 |
|
Recruitment Status :
Completed
First Posted : September 16, 2016
Last Update Posted : December 30, 2021
|
Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Sanofi
Bayer
Information provided by (Responsible Party):
Bobby Liaw, Icahn School of Medicine at Mount Sinai
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 15, 2021 |
| Actual Study Completion Date : | November 15, 2021 |